http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 10:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/DAT%E2%80%99s+Convoy+Platform+now+shows+reload+options+before+carriers+book/26633800.html <p align="center"><img alt="ConvoyPlatformReloads" height="565" src="https://ml.globenewswire.com/Resource/Download/2d5a3ed8-267c-4174-b9fe-4ae3b69d4122/grouped-reloads.png" width="600" data-dpi="96" data-caption="With earlier visibility into backhaul options, carriers can plan beyond the first leg, factor the full trip into their bidding decision, and avoid costly empty miles." data-filename="grouped reloads.png" /><br /></p> <p>PORTLAND, Ore., June 11, 2026 (GLOBE NEWSWIRE) -- DAT Freight &amp; Analytics has expanded the reloads feature in the Convoy Platform app, a trucking app that helps carriers book and haul freight, giving carriers a view of available freight near the delivery stop before they book a load. With earlier visibility into backhaul options, carriers can plan beyond the first http://www.streetinsider.com/Press+Releases/DAT%E2%80%99s+Convoy+Platform+now+shows+reload+options+before+carriers+book/26633800.html Thu, 11 Jun 2026 10:00:00 -0400 ROP http://www.streetinsider.com/Globe+Newswire/DAT%E2%80%99s+Convoy+Platform+now+shows+reload+options+before+carriers+book/26633800.html <p align="center"><img alt="ConvoyPlatformReloads" height="565" src="https://ml.globenewswire.com/Resource/Download/2d5a3ed8-267c-4174-b9fe-4ae3b69d4122/grouped-reloads.png" width="600" data-dpi="96" data-caption="With earlier visibility into backhaul options, carriers can plan beyond the first leg, factor the full trip into their bidding decision, and avoid costly empty miles." data-filename="grouped reloads.png" /><br /></p> <p>PORTLAND, Ore., June 11, 2026 (GLOBE NEWSWIRE) -- DAT Freight &amp; Analytics has expanded the reloads feature in the Convoy Platform app, a trucking app that helps carriers book and haul freight, giving carriers a view of available freight near the delivery stop before they book a load. With earlier visibility into backhaul options, carriers can plan beyond the first http://www.streetinsider.com/Globe+Newswire/DAT%E2%80%99s+Convoy+Platform+now+shows+reload+options+before+carriers+book/26633800.html Thu, 11 Jun 2026 10:00:00 -0400 ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html <p>The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to treat stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer. The agency granted priority review and is expected to make a decision by October 9, 2026.</p> <p>The application is based on the Phase III Alliance ATOMIC study, which showed that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone in patients with stage III dMMR colon cancer. The 36-month disease-free survival was 86% for the combination treatment versus http://www.streetinsider.com/FDA/FDA+grants+priority+review+for+Genentech%27s+Tecentriq+in+stage+III+colon+cancer/26631497.html Thu, 11 Jun 2026 01:05:18 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html <ul class="bwlistdisc"> <li> <i>Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone</i> </li> <li> <i>Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options</i> </li> <li> <i>If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery</i> </li> </ul> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has http://www.streetinsider.com/Press+Releases/FDA+Grants+Priority+Review+for+Genentech%E2%80%99s+Tecentriq+for+a+Certain+Type+of+Stage+III+Colon+Cancer/26631495.html Thu, 11 Jun 2026 01:05:00 -0400 A.06822034 A.09649487 A.40151759 A.50216717 A.60001765 O.00048429 O.00050368 O.00222322 O.20026344 O.20738543 O.48214193 RHHBY RO ROP